CNBX Pharmaceuticals Inc. (CNBXD)
Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014
Balance Sheet Date2025-Nov-302025-Aug-312025-May-312025-Feb-282024-Nov-302024-Aug-312024-May-312024-Feb-292021-Aug-312021-May-312021-Feb-282020-Nov-302020-Aug-312020-May-312020-Feb-292019-Nov-302019-Aug-312019-May-312019-Feb-282018-Nov-302018-Aug-312018-May-312018-Feb-282017-Nov-302017-Aug-312017-May-312017-Feb-282016-Nov-302016-Aug-312016-May-312016-Feb-292015-Nov-302015-Aug-312015-May-312015-Feb-282014-Nov-302014-Aug-312014-May-312014-Feb-28
Fiscal PeriodQ1-FY2026Q4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016Q2-FY2016Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014Q3-FY2014Q2-FY2014
Operating Cash Flow(47,408$)(28,545$)(52,019$)(51,664$)(39,077$)(48,250$)225$(71,846$)20,517$(18,591$)(581,819$)(616,117$)(702,340$)(592,637$)(713,959$)(575,679$)(723,630$)(761,687$)(868,673$)(818,635$)(739,337$)(667,135$)(621,497$)(465,624$)(434,597$)(452,974$)(343,467$)(205,443$)(167,701$)(146,956$)(31,277$)
Investing Cash Flow0$94,673$(1,196$)0$0$0$0$645,968$(943$)1,133,941$346,336$991,258$815,049$641,160$(3,855,704$)(740,195$)(1,296,376$)(700,257$)(98,265$)(639,402$)(4,470$)(34,695$)(89,347$)(1,733$)0$
Purchases of Property and Equipment0$0$0$0$0$3,710$
Financing Cash Flow40,000$30,008$19,992$80,000$30,000$1,260$1,259$24,993$65,028$14,994$0$1,250,000$1,206,750$0$0$0$0$0$(7$)0$67,466$7,149,811$500,000$(85,000$)1,050,000$(22,000$)555,553$2,917,876$458,500$405,980$
End Cash Position7,703$15,111$13,648$45,675$17,339$26,416$73,406$37,142$81,647$129,696$44,151$47,748$117,515$1,386,472$1,968,291$1,334,409$184,031$777,611$357,629$586,972$319,344$265,982$493,501$5,167,840$6,579,908$1,393,608$2,215,362$2,864,251$2,888,250$1,393,608$3,190,303$567,217$278,151$19,127$88,502$77,397$9,560$25,229$21,551$8,211$32,468$98,768$0$1,076$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(47,408$)(28,545$)(52,019$)(51,664$)(39,077$)(48,250$)225$(71,846$)20,517$(18,591$)(581,819$)(616,117$)(702,340$)(592,637$)(713,959$)(575,679$)(723,630$)(761,687$)(868,673$)(818,635$)(739,337$)(667,135$)(621,497$)(465,624$)(434,597$)(452,974$)(343,467$)(205,443$)(167,701$)(146,956$)(31,277$)